Search results for "Agoni"

showing 10 items of 2493 documents

Role of skeletal muscle-fibre type in regulation of glucose metabolism in middle-aged subjects with impaired glucose tolerance during a long-term exe…

2005

Aim: The aim of this study was to investigate the role of skeletal muscle fibre type in the regulation of glucose metabolism in middle-aged obese subjects with impaired glucose tolerance (IGT) during a 2-year exercise anddietary intervention. Methods: Muscle biopsies (musculus vastus lateralis) were taken from 22 subjects belonging to the intervention group of the Finnish Diabetes Prevention Study [1]. According to their myosin heavy chain (MHC) profile at the baseline, the subjects were divided into two groups: IGT s l o w (n = 10) with a high proportion of MHC I isoforms and IGT f a s t (n = 12) with a high proportion of MHC II isoforms in the vastus lateralis muscle. The intervention con…

AdultBlood GlucoseMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyDiet Reducingendocrine system diseasesVastus lateralis muscleEndocrinology Diabetes and MetabolismMuscle Fibers SkeletalCarbohydrate metabolismImpaired glucose toleranceGlycogen Synthase Kinase 3EndocrinologyInsulin resistanceDiabetes mellitusInternal medicineGlucose IntoleranceWeight LossInternal MedicinemedicineHumansAerobic exerciseObesityMuscle SkeletalGlycogen synthaseExerciseAgedMyosin Heavy Chainsbiologybusiness.industrynutritional and metabolic diseasesSkeletal muscleMiddle Agedmedicine.diseaseCombined Modality Therapymedicine.anatomical_structureEndocrinologybiology.proteinFemalebusinesshormones hormone substitutes and hormone antagonistsFollow-Up StudiesDiabetes, Obesity and Metabolism
researchProduct

Lack of plasmic beta-endorphin response to a gastronomic meal in healthy humans.

1991

Abstract In order to study the relationship between the endogenous opiate system and food intake in man, plasma concentrations of beta-endorphin were measured in ten healthy subjects. Time course of beta-endorphinemia was compared under the following conditions: basal (fasting), after an injection of pentagastrin (6 μg/kg), or after a gastronomic meal. No changes in plasma beta-endorphin or ACTH concentrations were observed with pentagastrin nor after the meal, despite the combination of very high sensory pleasure with intake of a very large amount of food. It is concluded that blood beta-endorphin concentration is not a sensitive index of the effects of food intake on the endogenous opioid…

AdultBlood GlucoseMaleendocrine systemmedicine.medical_specialtyHungerAppetiteExperimental and Cognitive PsychologyPeptide hormoneBehavioral Neurosciencechemistry.chemical_compoundEatingInternal medicinemedicineHumansPalatabilityEndogenous opioidMealbusiness.industrydigestive oral and skin physiologybeta-EndorphinPentagastrinAffectEndocrinologychemistryBasal (medicine)TasteReceptors Opioidbeta-EndorphinOpiatebusinessArousalEnergy Intakehormones hormone substitutes and hormone antagonistsmedicine.drugPhysiologybehavior
researchProduct

Correlation between different degree and duration of metabolic control and thyroid hormone levels in type 1 and type 2 diabetics.

1983

Thyroxine (T4), triiodothyronine (T3), reverse T3 (rT3) and HbA1c were assayed in 21 insulin-dependent (type 1) diabetics and in 45 non-insulin-dependent (type 2) diabetics with normal thyroid function and different levels of control, and were compared to values found in apparently healthy controls. rT3 and rT3/T3 ratio were significantly increased both in type 1 and type 2 diabetics. T3 and T4 were significantly lower in type 2 diabetics than in the controls. Significant positive correlations of HbA1c to rT3 (r = 0.63) and to rT3/T3 ratio (r = 0.53) were found in type 1, and in type 2 diabetics (HbA1c, rT3-r = 0.50), (HbA1c, rT3/T3-r = 0.37). There was no correlation between glycemia (BG),…

AdultBlood GlucoseMaleendocrine systemmedicine.medical_specialtyThyroid Hormonesendocrine system diseasesAdolescentTriiodothyronine ReverseEndocrinology Diabetes and MetabolismCorrelationEndocrinologyDiabetes mellitusInternal medicineInternal MedicinemedicineHumansAgedGlycated HemoglobinTriiodothyroninebusiness.industryThyroidType 2 Diabetes MellitusGeneral MedicineMiddle Agedmedicine.diseaseThyroxinemedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 1Diabetes Mellitus Type 2Thyroid hormonesMetabolic control analysisTriiodothyronineFemalebusinesshormones hormone substitutes and hormone antagonistsHormoneActa diabetologica latina
researchProduct

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin lev…

2013

OBJECTIVE: Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly diagnosed prolactinoma in relation to disease control and CAB dosage. DESIGN: This is a retrospective clinical-based therapy analysis. PATIENTS: Forty-three patients with prolactinoma (eight men, 35 women), aged 33·65 ± 11·23 years, were evaluated metabolically at baseline and after 12 months of CAB treatment. MEASUREMENTS: Body mass index (BMI), systolic and diastolic blood pressure, waist circumference (WC), lipid profile, haemoglobinA1c (…

AdultBlood GlucoseMalemedicine.medical_specialtyCabergolineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPituitary neoplasmSettore MED/13 - EndocrinologiaBody Mass IndexYoung AdultEndocrinologyInsulin resistanceInternal medicineCabergolineMedicineHumansPituitary NeoplasmsProlactinomaErgolinesProlactinomaAdiposityRetrospective Studiesmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryInsulinmedicine.diseaseLipidsProlactinBlood pressureEndocrinologyDopamine AgonistsMetabolomeFemaleInsulin ResistanceWaist CircumferencebusinessLipid profileBody mass indexmedicine.drugClinical endocrinology
researchProduct

Glycated serum proteins and glucose tolerance

1988

Glycated serum proteins (GSP), stable glycated hemoglobin (HbA1c) together with some metabolic parameters were evaluated in 120 subjects, 30 with normal glucose tolerance (NGT), 30 with impaired glucose tolerance (IGT), 30 with non-insulin-dependent diabetes mellitus (NIDD), and 30 with insulin-dependent diabetes mellitus (IDD). GSP levels were significantly higher in IGT, NIDD and IDD than in NGT. HbA1c levels were not significantly higher in IGT in comparison with NGT, but were significantly higher in NIDD and in IDD than in NGT and IGT. GSP correlated better than HbA1c with all metabolic parameters considered. Taking into account the distribution of the values, GSP showed a smaller overl…

AdultBlood GlucoseMalemedicine.medical_specialtyGlycosylationendocrine system diseasesEndocrinology Diabetes and MetabolismImpaired glucose toleranceHba1c levelchemistry.chemical_compoundEndocrinologystomatognathic systemReference ValuesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansTriglyceridesGlycated HemoglobinGlucose tolerance testmedicine.diagnostic_testbusiness.industryCholesterolnutritional and metabolic diseasesBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseBlood proteinsCholesterolDiabetes Mellitus Type 1EndocrinologyDiabetes Mellitus Type 2chemistryHyperglycemiaMetabolic control analysisFemaleGlycated hemoglobinbusinesshormones hormone substitutes and hormone antagonistsActa Diabetologica Latina
researchProduct

Sympathovagal balance and 1-h postload plasma glucose in normoglucose tolerant hypertensive patients.

2015

AIMS: Normoglucose tolerant (NGT) subjects with a 1-h postload plasma glucose (PLPG) value ≥155 mg/dL have an increased risk of type-2 diabetes and subclinical organ damage. Heart rate variability (HRV) reflects cardiac autonomic balance, frequently impaired in course of diabetes. At this time, no data support the association between 1-h PLPG and HRV; thus, we investigated the possible association between 1-h PLPG and HRV. METHODS: We enrolled 92 never-treated hypertensive subjects (56 women, 36 men), aged 55 ± 9.8 years. During OGTT, the patients underwent electrocardiographic recordings to evaluate HRV in the time domain (SDNN). Insulin sensitivity was assessed by Matsuda index. RESULTS: …

AdultBlood GlucoseMalemedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesglucose toleranceInsulin resistance Heart rate variability Glucose tolerance Essential hypertensionEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism030204 cardiovascular system & hematologyEssential hypertensionAutonomic Nervous Systeminsulin resistance heart rate variability glucose tolerance essential hypertensionImpaired glucose tolerance03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceHeart RateInternal medicineDiabetes mellitusinsulin resistanceGlucose IntoleranceInternal MedicineMedicineHeart rate variabilityHomeostasisHumansSubclinical infectionBalance (ability)Agedbusiness.industryInsulinheart rate variabilityessential hypertensionnutritional and metabolic diseasesGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseEndocrinologyDiabetes Mellitus Type 2HypertensionCardiologyFemalebusinesshormones hormone substitutes and hormone antagonists
researchProduct

Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: a 3-year follow-up study.

2003

Background: The objective of this study was to analyse the relationship of polymorphisms of the angiotensinogen (AGT) gene with the changes in microalbuminuria during 3 years of antihypertensive treatment in a group of young adults with essential hypertension. Methods: Essential hypertensives, less than 50 years old, never previously treated with antihypertensive drugs and in the absence of diabetes mellitus were included. After the initial evaluation, patients were treated using only nonpharmacological measures (n=23), only β-blockers (n=26), only angiotensin-converting enzyme inhibitors (ACEi) (n=57) or a combination of treatments (n=25). The office blood pressure, biochemical profile and…

AdultBlood GlucoseMalemedicine.medical_specialtyTime FactorsGenotypeAdrenergic beta-AntagonistsAngiotensinogenAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionExcretionDiabetes mellitusInternal medicineInternal MedicinemedicineAlbuminuriaHumansAntihypertensive AgentsProteinuriaPolymorphism Geneticbusiness.industrymedicine.diseaseEndocrinologyBlood pressureTreatment OutcomeACE inhibitorHypertensionMicroalbuminuriaFemaleGene polymorphismmedicine.symptombusinessmedicine.drugFollow-Up StudiesJournal of human hypertension
researchProduct

Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.

2003

Pharmacokinetic and pharmacodynamic profiles of the rapid-acting insulin analogues lispro and aspart were compared in a randomized, double-blind crossover study of 20 fasting healthy men following a single subcutaneous injection. Either insulin lispro or aspart, 0.05 U/kg-body-weight, was injected subcutaneously and followed by determination of 5-h profiles of plasma glucose, serum C-peptide and insulin concentrations. Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l). For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRadioimmunoassayInsulin aspartSubcutaneous injectionEndocrinologyPharmacokineticsDouble-Blind MethodDiabetes mellitusInternal medicineInternal MedicinemedicineInsulin lisproHumansHypoglycemic AgentsInsulinInsulin AspartCross-Over StudiesInsulin LisproC-Peptidebusiness.industryInsulindigestive oral and skin physiologynutritional and metabolic diseasesGeneral Medicinemedicine.diseaseCrossover studyEndocrinologyPharmacodynamicsbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Platelet-activating factor type activity in plasma from patients with septicemia and other diseases

1991

The purpose of the present study was to determine whether increased levels of platelet-activating factor (PAF) type activity can be detected in plasma from patients with septicemia and other diseases. A level of PAF below 0.5 ng/mL of plasma was considered normal. We found that plasma from a patient with adverse anaphylactoidic reaction to intravenous analgetics contained 2.1 ng PAF/mL. In seven patients with septicemia, including urosepsis, endocarditis and peritonitis, and with positive blood culture, increased plasma PAF levels (1-20 ng PAF/mL) were observed. Other patients with clinical indications of septicemia had negative blood cultures and/or increased levels of C-reactive protein (…

AdultBlood PlateletsMalemedicine.medical_specialtyPlatelet AggregationClinical chemistryPeritonitisBacteremiaBiochemistrySepsischemistry.chemical_compoundReference ValuesInternal medicinemedicineAnimalsHumansPlateletPlatelet Activating FactorPlatelet-activating factorPlatelet CountSeptic shockbusiness.industryOrganic ChemistryAntagonistAzepinesCell BiologyMiddle AgedTriazolesrespiratory systemmedicine.diseaseThrombocytopenic purpuraC-Reactive ProteinEndocrinologyPurpura ThrombocytopenicchemistryImmunologyFemalelipids (amino acids peptides and proteins)RabbitsbusinessLipids
researchProduct

MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing

2000

Beta-blocker therapy results in a functional benefit in patients with heart failure (CHF) due to idiopathic dilated cardiomyopathy (DCM). This study assessed if similar effects were observed in patients with ischemic heart disease (CAD), NYHA II–III after 6 months of therapy with metoprolol. Methods and results: Fifty-two patients with CHF secondary to DCM (26 patients) and CAD (26 patients) and a left ventricular ejection fraction (EF) < 40% were enrolled in the placebo-controlled study. The study medication was titrated over 6 weeks, the mean final dosage was 135 mg/day. Three patients died due to cardiogenic shock, two received placebo and one metoprolol. Eight patients did not complete …

AdultCardiomyopathy DilatedMaleCardiac function curvemedicine.medical_specialtyCardiac VolumeAdrenergic beta-AntagonistsMyocardial IschemiaCardiomyopathyVentricular Function LeftDouble-Blind MethodInternal medicineIdiopathic dilated cardiomyopathyHeart ratemedicineHumansProspective Studiescardiovascular diseasesAgedMetoprololHeart FailureEjection fractionbusiness.industryCardiogenic shockMiddle Agedmedicine.diseaseHeart failureExercise Testcardiovascular systemCardiologyFemaleCardiology and Cardiovascular Medicinebusinesshuman activitiesMetoprololcirculatory and respiratory physiologymedicine.drugEuropean Journal of Heart Failure
researchProduct